Start-ups and spin-outs in Life Sciences
We have a successful record in launching spin-out companies which has helped drive the establishment of a life sciences cluster which makes a major contribution to the Tay Cities regional economy.
Developing drugs using ground-breaking targeted protein degradation technology from the laboratory of Professor Alessio Ciulli. Amphista received £38M of series-B investment in 2021 and was Scrip Awards Financing Deal of the Year.
In 2022, they announced collaborations with Merck Healthcare and Bristol Myers Squibb potentially worth $2 billion.
Based on the work of Professor Andrew Hopkins, Exscientia develops and applies pioneering artificial intelligence (AI) drug design methodologies that enhance the efficacy and the efficiency of drug discovery for the pharmaceutical industry.
Exscientia collaborates with leading pharmaceutical companies and underwent Europe’s largest IPO on the NASDAQ in 2021. With a market capitalisation of over $2Bn, it is now one of the UK’s largest Biotech companies.
Ten Bio Ltd
An exciting new biotech spin out company offering innovative human skin explant technology that allows superior retention of in vivo physiological characteristics for testing of pharmaceuticals and cosmetics products, reducing the need for testing in animal models.
In 2021, they announced near £1 million investment from TRICAPITAL LTD and Scottish Enterprise.